Livagen is described as a synthetic four-amino-acid peptide, also called Lys-Glu-Asp-Ala or KEDA. The supplied evidence connects it mainly with laboratory research on gene expression, cellular aging, and liver-related bioregulator use, but does not provide clinical trial evidence showing benefit in people.

How is Livagen proposed to work?

The proposed mechanism is epigenetic and remains unconfirmed. In vitro reports cited by the source describe changes in compact chromatin regions and ribosomal gene activity in cells from older donors. The supplied evidence frames this as mechanistic cell research, not as an established clinical mechanism.

Is Livagen FDA approved?

No. The source states that Livagen is not FDA approved and classifies the evidence as preclinical, while also noting reported supplement approval in Russia.

What side effects are reported for Livagen?

The source lists Livagen as generally well tolerated but also notes limited safety information outside Russia. It also lists lack of FDA approval, which is a regulatory status rather than an adverse effect.

What dose is reported for Livagen?

The source reports community use of 10-20 mg daily, once or twice daily, with oral capsule or sublingual administration and 10-30 day cycles. This is reported-use information only and is not supported by supplied randomized clinical trial evidence.

Bioregulators Preclinical - animal studies only

Livagen

Also known as: Lys-Glu-Asp-Ala, KEDA

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Synthetic KEDA tetrapeptide bioregulator with preclinical epigenetic research claims.

Status

Preclinical

Evidence level: animal studies

Typical dose

10–20mg

Oral capsules or sublingual

Researched for

Gene expression, cellular aging, liver health

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Promising animal research, limited human data

Use the tools

In plain language

Synthetic tetrapeptide also known as Lys-Glu-Asp-Ala or KEDA.
Categorized by the source as a bioregulator.
Evidence is described as , with no supplied randomized human trial evidence.
Reported research areas include gene expression, cellular aging, and liver health.
Source-reported use is 10-20 mg daily, once or twice daily, orally or sublingually.

How it's thought to work

Livagen is presented as a short bioregulator with a proposed epigenetic mode of action. The supplied source describes findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.

What the research shows

Where the research stands

The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.

What it shows

✓ Animal studies

Promising animal research, limited human data

△ Limitations

Animal study doses may not translate directly to humans.

Bottom line: Preclinical research; reported as approved in Russia as a supplement Not FDA approved

Typical dosing

CommunityCommunity dataset

10–20 mg

daily

10 mgfull range seen20 mg

Community-reported dosing for Livagen; not established by randomized clinical trial evidence in the supplied source. · Oral capsules or sublingual · 10-30 day cycles

Research dosing

Animal studies onlyAnimal studies only - may not translate to humans

Doses observed in studies

10-20 mg daily

Animal study doses may not translate directly to humans.

Duration: 10-30 day cycles
Administration: Oral capsules or sublingual

Timing & administration

Best time to take

Morning on an empty stomach

Once or twice daily

Food recommendation

Take on an empty stomach

Why this timing?

The source reports fasted use for peptide bioregulators as an absorption-oriented practice; supplied evidence does not validate this timing in clinical trials.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally reported as well tolerated
Limited safety data outside Russia
Not FDA approved

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

H-Lys-Glu-Asp-Ala-OH (KEDA)

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Livagen

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Livagen

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions

What is Livagen?